Elan complete royalty rights deal
Irish pharmaceutical firm Elan has completed the acquisition of the royalty rights of three drugs from Pharma Operating.
Elan said this morning that it has completed the purchase of the rights in respect of Zonegran, Frova and Zanaflex for $99.6m (€83.75m).